Tilray Brands (TLRY) Income from Continuing Operations (2017 - 2026)
Tilray Brands (TLRY) posted Income from Continuing Operations of 25233000.0 for Q1 2026, up 42.01% on a QoQ basis from 43509000.0 in Q4 2025, and up 96.82% year-over-year from 12820332.12 in Q1 2025.
Tilray Brands (TLRY) Income from Continuing Operations (2017 - 2026) Analysis & Trends
Tilray Brands' Income from Continuing Operations history runs 10 years deep, the most recent figure standing at 25233000.0 for Q1 2026.
- Quarterly Income from Continuing Operations rose 96.82% year-over-year to 25233000.0 in Q1 2026, while the trailing twelve-month figure through Feb 2026 was 1460635000.0 (down 72.77% YoY) and the FY2025 annual result came in at 2306867000.0, down 1559.72% from the prior year.
- Income from Continuing Operations was 25233000.0 for Q1 2026 at Tilray Brands, up from 43509000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 816311000.0 in Q2 2023 and bottomed at 1393406000.0 in Q2 2025.
- A 5-year average of 190690058.82 and a median of 55863000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Peak annual rise in Income from Continuing Operations reached 425.45% in 2023, while the deepest fall reached 2378.71% in 2023.
- Tilray Brands' Income from Continuing Operations stood at 85061000.0 in 2022, then soared by 45.71% to 46183000.0 in 2023, then tumbled by 84.65% to 85275000.0 in 2024, then soared by 48.98% to 43509000.0 in 2025, then surged by 42.01% to 25233000.0 in 2026.
- Business Quant data shows TLRY's Income from Continuing Operations at 25233000.0 in Q1 2026, 43509000.0 in Q4 2025, and 1513000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 274.90 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Tilray Brands | 465.02 Mn | 373.06 Mn | 54.95 Mn | -25.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | -25.23 Mn |
| Nov 30, 2025 | -43.51 Mn |
| Aug 31, 2025 | 1.51 Mn |
| May 31, 2025 | -1.39 Bn |
| Feb 28, 2025 | -793.53 Mn |
| Nov 30, 2024 | -85.28 Mn |
| Aug 31, 2024 | -34.65 Mn |
| May 31, 2024 | 68.04 Mn |
| Feb 29, 2024 | -104.98 Mn |
| Nov 30, 2023 | -46.18 Mn |
| Aug 31, 2023 | -55.86 Mn |
| May 31, 2023 | 816.31 Mn |
| Feb 28, 2023 | -1.20 Bn |
| Nov 30, 2022 | -85.06 Mn |
| Aug 31, 2022 | -65.79 Mn |
| May 31, 2022 | -250.82 Mn |
| Feb 28, 2022 | 52.48 Mn |
| Nov 30, 2021 | 5.80 Mn |
| Aug 31, 2021 | -34.60 Mn |
| May 31, 2021 | 345.90 Mn |